- Gallup: Take Care Clinics top in customer service
- The Little Clinic adds new insurance provider to accepted plans
- Rite Aid takes a bite out of obesity; relaunches weight-loss program for New Year
- More progress needed in health information technology
- Bartell to cease filling Medicaid prescriptions at 15 locations
SAN DIEGO An advisory committee of the Food and Drug Administration has given a thumbs-down to a drug for treating obesity.
Eisai and Arena Pharmaceuticals said Thursday that the FDA’s Endocrinologic and Metabolic Drugs Advisory Committee voted 9-5 to recommend against approval of the drug lorcaserin, saying clinical trial data did not adequately show that its benefits would outweigh its risks.
While the FDA is not bound by advisory committee recommendations, it takes them into account when deciding whether or not to grant approval to a drug.